Introduction
============

Viral infections in children and young adults are common and generally uneventful. In most instances, the patients recover and either eliminate the virus or incorporate it in a latent or persistent form without further problems. Although viruses are obligate intracellular parasites and rely entirely on the metabolic machinery of the host cell, they usually do not cause much harm. The main reason is that our body is not defenseless but makes use of numerous measures to keep viruses at bay. As we know, the type I interferon system is a major player in antiviral defense against all kinds of viruses. Virus-infected cells synthesize and secrete type I interferons (IFN-α/β) which warn the body of the dangerous intruders. Secreted IFNs circulate in the body and cause susceptible cells to express potent antiviral mechanisms which limit further viral growth and spread. IFN was discovered almost 50 years ago by Isaacs and Lindenmann as a cytokine interfering with virus replication ([@bib73]). Since then, much progress has been made in demonstrating how IFNs are induced and how they work. However, only now we begin to appreciate to what extent viruses modulate the IFN response they evoke in the first place. Clearly, viruses would not be successful pathogens if they had not evolved efficient escape strategies allowing them to suppress IFN production, to down-modulate IFN signaling and to block the action of antiviral effector proteins. It is becoming increasingly clear that the IFN antagonistic properties determine viral virulence to a great extent and may contribute to interspecies transmission of so-called emerging and reemerging viruses. Here, we summarize recent highlights in our understanding of how cells defend themselves against viral intruders and how viruses manage to survive in the face of the powerful IFN system.

The amazing power of the interferon system
==========================================

The type I IFN system is indispensable for vertebrates to control viral infections. This is best illustrated in knockout mice which are unresponsive to IFN-α/β due to targeted deletions in the type I IFN receptor ([@bib110]). These mice quickly succumb to viral infections despite having a normal adaptive immune system ([@bib18], [@bib20], [@bib54], [@bib71], [@bib110], [@bib131], [@bib166]). Likewise, humans die of viral disease at an early age if they happen to acquire genetic defects of the IFN system ([@bib40]). The importance of type I IFNs is further demonstrated in instances where disruption of a single IFN-effector gene causes a complete loss of innate immunity against a particular type of virus, leading to overwhelming infection and rapid death. A telling case is increased susceptibility to influenza and influenza-like viruses found in inbred mouse strains due to a defect in the IFN-regulated *Mx1* gene ([@bib98], [@bib147])*.* Susceptible animals are equipped with the full armament of innate and adaptive immunity with the exception of Mx and resist all sorts of viruses but not orthomyxoviruses ([@bib59], [@bib62]). Transgenic introduction of mouse or human Mx is sufficient to turn susceptible mice into resistant animals ([@bib6], [@bib118]). More importantly, constitutive expression of human MxA in an otherwise IFN-non-responsive animal confers full protection, demonstrating the exquisite power of a single effector molecule of the human IFN system in an otherwise susceptible host ([@bib64]). A single autosomal dominant gene locus, designated *Flv/Wnv*, is responsible for natural resistance of mice against infection with West Nile virus (WNV) and other flaviviruses ([@bib22]). The gene was recently identified as *Oas1b*, a member of a large IFN-regulated gene family encoding 2′-5′-oligoadenylate synthetases (2-5 OAS) known to play an important role in antiviral defense ([@bib104], [@bib119]). As in the case of the Mx GTPase, OAS1b has antiviral activity and directly mediates inhibition of WNV replication ([@bib102], [@bib119]). In recent years, genetic analysis of innate immune responses has exploded and has generated a wealth of new information, as discussed below.

Pathways leading to IFN gene expression
=======================================

Induction of type I (α/β) IFN gene expression is tightly regulated. Recent findings suggest that cells make use of two major but distinct cellular signal transduction pathways to sense viruses and activate their type I IFN genes. Most cells of the body including fibroblasts, hepatocytes and conventional dendritic cells (cDCs) use the so-called classical pathway. They have intracellular sensors that, upon infection, detect viral components in the cytoplasm and activate the main interferon regulatory transcription factors IRF-3 and NF-kB which in turn transactivate IFN-β gene expression. Infected cells secrete mainly IFN-β as an initial response to infection but switch to IFN-α during the subsequent amplification phase of the IFN response ([@bib103]). In contrast, plasmacytoid dendritic cells (pDCs) use Toll-like receptors (TLRs) expressed on the cell surface or in endosomes to sense extracellular or engulfed viral material. TLR signaling of pDCs primarily involves the adaptor protein MyD88 and activates IRF-7 which is constitutively expressed in pDCs and serves as a master regulator of IFN-α/β gene expression ([@bib68]). This cell type predominantly secretes high levels of IFN-α and represents the so-called natural interferon producing cells of the body ([@bib30], [@bib38]). Both pathways play important roles during infection and are presently being fully explored.

Classical pathway
-----------------

The classical pathway of type I IFN induction is best understood for IFN-β gene expression in fibroblasts ([Fig. 1](#fig1){ref-type="fig"} ). In infected cells, a signaling chain is activated by double-stranded RNA (dsRNA) molecules which are generated as intermediates of viral transcription. Two intracellular RNA helicases, RIG-I ([@bib180]) and MDA5 ([@bib5]), act as sentinels for viral dsRNA detection. The two related helicases are apparently non-redundant and seem to function in parallel, having a degree of virus specificity ([@bib181]). RIG-I and MDA5 are ubiquitously expressed in most tissues and are inducible by IFNs which allows autocrine and paracrine amplification of the sensing system. A third member of the RIG-I helicase family, LGP2, is a natural inhibitor which presumably masks the viral dsRNA from recognition by RIG-I or MDA5 and serves as a negative regulator of IFN gene expression ([@bib127], [@bib181]). RIG-I and MDA5 both contain two N-terminal caspase-recruiting domain (CARD)-like regions and a C-terminal DExD/H box RNA helicase domain ([@bib5], [@bib180]). RNA-binding to the helicase domain most likely induces a conformational change which enables that CARD domain to interact with CARD-like domains of downstream signaling partners ([@bib79], [@bib180]). Indeed, one interaction partner has just been identified independently by two groups. The novel protein is required to mediate RIG-I and MDA5 signals to downstream factors and is therefore called either IPS-1 for "interferon-β-promoter stimulator 1" ([@bib80]) or MAVS for "mitochondrial antiviral signaling" molecule ([@bib138]). It is identical to an uncharacterized protein previously recognized to be involved in NF-kB promoter activation ([@bib106]). IPS-1/MAVS has a CARD-like domain which binds to RIG-I and MDA5 and a C-terminal region which interacts with FADD and RIP1 which are both involved in NF-kB signaling ([@bib80]). Surprisingly, IPS-1/MAVS localizes to the outer mitochondrial membrane via a C-terminal transmembrane domain. Membrane association and localization to mitochondria is shown to be essential for function ([@bib138]). These findings are intriguing, as they link IFN production and innate immune responses to mitochondrial activity. It is conceivable that the membrane localization of IPS-1/MAVS is advantageous as it may keep the interacting RNA-sensing helicases close to the viral replication factories which often develop in association with intracellullar membranes.Fig. 1Type I IFN induction, signaling and action. Left panel: dsRNA, a characteristic by-product of virus replication, leads to activation of the transcription factors NF-κB, IRF-3 and AP-1 (not shown). The cooperative action of these factors is required for full activation of the IFN-β promoter. IRF-3 is phosphorylated by the kinases IKKε and TBK-1 which in turn are activated by the RNA-sensing complex of RIG-I, MDA5 and IPS-1/MAVS. A second signaling pathway involves endosomal TLR-3 and TRIF. Right panel: Newly synthesized IFN-β binds to the type I IFN receptor (IFNAR) and activates the expression of numerous ISGs via the JAK/STAT pathway. IRF-7 amplifies the IFN response by inducing the expression of several IFN-β subtypes. SOCS and PIAS are negative regulators of the JAK-STAT pathway. Mx, ISG20, OAS and PKR are examples of proteins with antiviral activity. For details see text.

The downstream molecules interacting with IPS-1/MAVS are not yet known. However, IPS-1/MAVS leads indirectly to activation of the IRF-3 kinases ([Fig. 1](#fig1){ref-type="fig"}) ([@bib80], [@bib138]). Two IκB kinase (IKK)-related kinases, IKKε and TANK-binding kinase-1 (TBK-1), are known to phosphorylate the transcription factor IRF-3 ([@bib45], [@bib140]). IRF-3 is a member of the IFN regulatory factor (IRF) family and plays a central role in the activation of the IFN-β promoter ([@bib95], [@bib135], [@bib170], [@bib171], [@bib179]). Phosphorylated IRF-3 homodimerizes and moves into the nucleus where it recruits the transcriptional coactivators p300 and CREB-binding protein (CBP) to initiate IFN-β mRNA synthesis ([@bib66], [@bib152]). In addition, NF-κB and AP-1 are recruited in a dsRNA-dependent way ([@bib27]). Together these transcription factors strongly up-regulate IFN-α/β gene expression. This initially produced "first-wave" IFN triggers expression of a related factor, IRF-7, which is normally not present in most cells or at best in very low amounts ([@bib134]). Genetic evidence has recently shown that IRF-7 is the master regulator of IFN gene expression and that IRF-3 most likely cooperates with IRF-7 for full activity ([@bib68]). IRF-7 is activated in the same way as IRF-3 ([@bib74], [@bib144], [@bib159]) and is responsible for a positive-feedback loop that initiates the synthesis of several IFN-α subtypes as the "second-wave" IFNs ([@bib103], [@bib133]).

Some cells of the hematopoietic system such as cDCs preferentially express TLR3 and can sense viral and other dsRNA molecules in the endocytic compartment ([Fig 1](#fig1){ref-type="fig"}). Ligand-induced triggering of TLR3 by dsRNA proceeds via the adaptor molecule TRIF which bypasses IPS-1/MAVS and directly activates the kinase TBK-1. This RIG-I-independent process also leads to phosphorylation and nuclear translocation of IRF-3 and IFN-β gene expression. The main difference is that TLR-3-expressing cells do not need to get infected to produce type I IFNs but can respond to viral RNA from inactivated virus particles or dead cells provided they are taken up in the endosomal compartment ([@bib137]).

TLR pathway in plasmacytoid dendritic cells
-------------------------------------------

pDCs are specialized IFN producers and represent a major source of IFN-α in humans ([@bib30]). They sense the presence of RNA or DNA viruses by TLRs expressed in endosomes ([@bib13], [@bib19]). Human pDCs mostly express the TLR9 subfamily members TLR7, TLR8 and TLR9 which recognize viral single-stranded (ss) RNA (TLR7,8) or double-stranded CpG-rich DNA (TLR9), respectively ([@bib75]). Upon activation, TLR7, 8 and 9 signal through their adaptor molecule MyD88 which forms a complex with TRAF6 and IRF-7 ([Fig. 2](#fig2){ref-type="fig"} ). IRF-7 is phosphorylated by IRAK-1, an additional component of this receptor-associated multiprotein complex, and transcriptionally activates multiple IFN-α genes ([@bib75], [@bib162]). A key difference between pDCs and other cell types is their capacity to constitutively express considerable amounts of IRF-7 ([@bib81], [@bib121]). IRF-7 and also IRF-8 are further up-regulated in response to IFN and together generate a positive feed back loop for high IFN-α and IFN-β production ([@bib8], [@bib161]).Fig. 2TLR signaling pathway for IFN-α production in plasmacytoid dendritic cells (pDCs). TLR7 and TLR8 respond to RNA viruses by recognizing ssRNA in endosomes. In contrast, TLR9 responds to DNA viruses by recognizing CpG-rich sequences. The receptors transmit their signals through an associated multiprotein complex containing the adaptor protein MyD88 and the transcription factor IRF-7. In contrast to most other cells, pDCs constitutively express IRF-7 ([@bib81], [@bib121]). Some pathogenic viruses interfere with this pathway. See text for details.

Another distinguishing feature is the recent finding that ligand-bound TLR-9 and presumably also TLR-7/TLR8 remain active in the endosomal compartment for a long time period, whereas they are rapidly translocated to lysosomes and degraded in other cell types ([@bib67]). It is perhaps not surprising that some viruses which are known to cause prolonged immunosuppression or immune imbalances should target pDCs and inhibit IFN production induced by the TLR-MyD88-IRF-7 pathway ([Fig. 2](#fig2){ref-type="fig"}), because type I IFNs play a major role in shaping adaptive immune responses, in addition to their function in innate immunity ([@bib89]). Recent examples are measles virus and respiratory syncytial virus which block IFN production in pDCs by an as yet unknown mechanism ([@bib136]).

IFN receptor signaling
======================

The IFN receptor signaling pathway is now firmly established and has appropriately been described in comprehensive reviews ([@bib132], [@bib148]). IFN-β and the multiple IFN-α subspecies activate a common type I IFN receptor (IFNAR) which sends a signal to the nucleus through the so-called JAK-STAT pathway ([Fig. 1](#fig1){ref-type="fig"}). The STAT proteins are latent cytoplasmic transcription factors which become phosphorylated by the Janus kinases JAK-1 and TYK-2. Phosphorylated STAT-1 and STAT-2 recruit a third factor, IRF-9 (or p48), to form a complex known as IFN-stimulated gene factor 3 (ISGF-3) which translocates to the nucleus and binds to the IFN-stimulated response element (ISRE) in the promoter region of interferon-stimulated genes (ISGs). Specialized proteins serve as negative regulators and inhibitors of the JAK-STAT pathway. The suppressor of cytokine signaling (SOCS) proteins prevent STAT activation ([@bib86]) whereas protein inhibitor of activated STAT (PIAS) family members function as small ubiquitin-like modifier (SUMO) E3 ligases and inhibit the transcriptional activity of STATs ([@bib142]). Interestingly, some of these inhibitors are exploited by viruses to down-regulate IFN action (see below). Of great interest in this context is a recent genetic analysis of *Drosophila* C virus infection in its natural host *Drosophila melanogaster*, because the findings demonstrate for the first time a conserved function of the JAK-STAT signaling pathway in insect antiviral immunity ([@bib39]). It remains to be seen whether insect viruses possess evasion strategies similar to those found in vertebrate viruses.

IFN-stimulated gene products with antiviral activity
====================================================

Type I IFNs activate the expression of several hundred IFN-stimulated genes (ISGs) ([@bib34], [@bib36]) some of which code for antiviral proteins ([Fig. 1](#fig1){ref-type="fig"}). To date, three antiviral pathways have been firmly established. These comprise the protein kinase R (PKR) ([@bib174]), the 2-5 OAS/RNaseL system ([@bib143]) and the Mx proteins ([@bib60], [@bib73]). Mx proteins belong to the superfamily of dynamin-like large GTPases and have been discovered as mediators of genetic resistance against orthomyxoviruses in mice. Their importance for host survival following infection with certain RNA viruses has been amply demonstrated ([@bib7], [@bib64], [@bib118]) but their exact mode of action is still unknown. The relevance of the OAS/RNaseL and PKR systems in the IFN response to viral infection is well documented both in tissue culture and animal experiments. In addition, their importance is highlighted by the fact that most viruses have evolved specific mechanisms to counteract their activities (see below). Mice lacking one of these components show increased susceptibility to viral infections ([@bib177], [@bib184]). Nevertheless, cells from so-called triple knock-out mice lacking PKR, RNaseL and Mx still exhibit a limited IFN-induced antiviral state, indicating that additional antiviral pathways exist ([@bib185]). Additional proteins with potentially important antiviral activities are ISG20 ([@bib42]), promyelocytic leukemia protein (PML) ([@bib123]), guanylate-binding protein 1 (GBP-1) ([@bib3]), P56 ([@bib56], [@bib69]) and RNA-specific adenosine deaminase 1 (ADAR1) ([@bib132]). P56 binds a subunit of the eukaryotic translation initiation factor eIF3 and thereby suppresses viral as well as cellular RNA translation ([@bib69], [@bib169]). Importantly, both P56 and ADAR1 are able to limit hepatitis C virus (HCV) replication to some degree ([@bib158], [@bib169]).

Viral interference with cellular IFN responses
==============================================

Most viruses need to multiply extensively to establish a solid infection in the newly infected host and to provide an outcrop of progeny virus for host-to-host transmission, or else to secure viral persistence or latency. How can a virus reach this goal in the presence of a powerful innate immune response? The answer is that viruses have learned to cope with the IFN system. Shortly after the discovery that heat-inactivated influenza viruses would induce IFN ([@bib73]), Jean Lindenmann reported that infection of cells with a live influenza virus inhibited the subsequent induction of IFN by an inactivated virus. He called this puzzling phenomenon "inverse interference" ([@bib97]). It is now evident that most viruses have evolved means to down-regulate IFN responses. In many cases they use non-structural viral proteins for that purpose which are otherwise non-essential for virus growth. This strategy can be exploited in the laboratory to generate mutant viruses that lack the relevant non-essential proteins. Such viruses still grow in IFN-non-responsive cells or organisms but are highly attenuated in IFN-competent hosts. Using such an approach, several laboratories have already successfully produced novel vaccine candidates lacking proteins with IFN-antagonistic activity ([@bib44], [@bib156], [@bib165]). Current genetic analyses of many different viruses are revealing an ever-growing number of IFN-antagonistic proteins that target virtually all components of the IFN system. These IFN antagonists are often multifunctional proteins that interact with multiple viral or host cell components and are involved in regulating many different functions in infected cells. For example the NS1 of FLUAV is pleiotropic since it not only binds to and sequesters dsRNA molecules to prevent induction of IFNs ([@bib49], [@bib50], [@bib155], [@bib168]) but also inhibits the 3′ end processing of cellular pre-mRNAs, regulates the virus replication cycle and enhances translation initiation of viral mRNAs ([@bib85]). Comprehensive reviews have recently dealt with these issues ([@bib11], [@bib31], [@bib47], [@bib65], [@bib173]). Here we will address some general points.

[Fig. 3](#fig3){ref-type="fig"} illustrates the range of activities mediated by IFN antagonists of various viruses. Only a few examples are listed but they demonstrate several important points. First, viral proteins or functions have been identified that cover the whole spectrum of the IFN response in infected cells. Second, a single viral protein may inhibit quite different components of the IFN induction and signaling cascade. Third, a given virus may display more than one IFN-antagonistic activity targeting different pathways. Good examples are the V proteins of some paramyxoviruses which bind to the dsRNA-sensing helicase MDA5 and thereby block induction of IFN ([@bib5]) but also provoke the ubiquitinylation and subsequent degradation of STAT1 in a complex reaction ([@bib37], [@bib114], [@bib122], [@bib163]). The NSs protein of Rift valley fever virus is a major virulence factor ([@bib18]) and blocks IFN production by inhibiting the basic cellular transcription machinery ([@bib14], [@bib90]). Surprisingly, it also activates the cellular suppressor of STAT activation, SOCS-1, to impede IFN signaling (Michèle Bouloy, personal communication). Likewise, HSV-1 induces SOCS-3 to down-regulate STAT and JAK phosphorylation ([@bib178]). Interestingly, the core protein of HCV also appears to activate SOCS-3 ([@bib15]), while the NS3/4A protease of HCV inhibits RIG-I signaling and has also the ability to disrupt TLR3 signaling by inducing cleavage of the adaptor protein TRIF ([@bib21], [@bib46], [@bib94]). The NS3/4A protease is essential to cleave the non-structural proteins from the HCV polyprotein synthesized on intracellular membranes and may also lead to degradation of the membrane-bound cellular IPS1/MAVS complexes.Fig. 3Viral inhibitors of the virus-induced IFN-α/β response loop: Viral gene products interfere with the type I IFN system at all levels. The following viral IFN antagonists are shown in clockwise order: NS1 of FLUAV ([@bib49], [@bib50], [@bib155], [@bib168]), NS1 of FLUBV ([@bib32]), E3L VV ([@bib144], [@bib175]), V of paramyxoviruses ([@bib5]), NS3/4A of HCV ([@bib21], [@bib46]), VP35 of EBOV ([@bib12]), P of RV ([@bib23]), P of BDV ([@bib164]), V, W of Nipah virus ([@bib117], [@bib141]), NS1/NS2 of RSV ([@bib17], [@bib145], [@bib165]), leader protein of TMEV ([@bib35], [@bib167]), ML of THOV (Hagmaier, 2003 \#89;Jennings, 2004 \#233;Pichlmair, 2004 \#247), NPro of CSFV ([@bib88], [@bib129], [@bib130]), vIRF and ORF45 of HHV-8 ([@bib24], [@bib25], [@bib92], [@bib101], [@bib100], [@bib186], [@bib188]), E6 of HPV16 ([@bib126]), BZLF-1 of EBV ([@bib58]), M of VSV ([@bib1], [@bib183]), 3C^Pro^ of PV ([@bib28], [@bib176]), NSs of BUNV ([@bib160], [@bib172]), NSs of RVFV, ([@bib14], [@bib18], [@bib90]), B18 and B8 of VV ([@bib2], [@bib153]), JEV, WNV ([@bib57], [@bib96]), E6 of HPV18 ([@bib93]), core protein of HCV ([@bib15], [@bib82], [@bib107], [@bib108]), HSV-1 ([@bib178]), NSs of RVFV (M. Bouloy, pers. communication), V, C, N of paramyxoviruses ([@bib4], [@bib37], [@bib51], [@bib52], [@bib53], [@bib78], [@bib87], [@bib114], [@bib115], [@bib124], [@bib125], [@bib139], [@bib141], [@bib154]), NS4B of DHFV, WNV, and YFV ([@bib77], [@bib112], [@bib113]), E1A AdV ([@bib91], [@bib99]), NS5A and E2 of HCV ([@bib48], [@bib157]), EBER of EBV ([@bib41]), VA of AdV ([@bib83], [@bib105]), K3L of VV ([@bib33]). Not shown: Tat and TAR of HIV interfere with PKR activation ([@bib55], [@bib128]). γ34.5 protein of HSV-1 reverts the translational block mediated by PKR ([@bib63]). NS1 of influenza B virus targets the IFN-induced ubiquitin-like modifier ISG15, the significance of which remains to be established ([@bib85]). The M27 gene product of mouse cytomegalovirus binds and down-regulates STAT-2 ([@bib187]). Unknown gene products of hepatitis A virus and SARS-coronavirus inhibit IRF-3 activation ([@bib43], [@bib146]).

In many negative-strand RNA viruses, the phosphoprotein P, an essential component of the viral polymerase complex, is the main IFN antagonist. For example, the P protein of Rabies virus prevents IRF-3 phosphorylation by TBK-1 ([@bib23]). Likewise, the P protein (called VP35) of Ebola virus (EBOV) interferes with IRF-3 activation ([@bib12]). The P protein of Borna disease virus (BDV) directly binds to TBK-1 and reduces its activity ([@bib164]). A different strategy to block cellular IRF-3 is used by certain herpesviruses. Human herpes virus 8 (HHV-8), the causative agent of Kaposi sarcoma, displays viral IRF homologues, termed vIRFs, which either mimic their cellular counterparts or exert a dominant-negative effect ([@bib24], [@bib25], [@bib92], [@bib101], [@bib100], [@bib188]). Finally, a far-reaching approach is used by the large poxviruses. They can afford to express soluble IFN-binding proteins which compete with the cellular receptor for its IFN ligand ([@bib2], [@bib153]). These "viroceptors" neutralize whatever IFN is secreted from cells. They prevent the autocrine IFN amplification loop and -- more importantly -- the establishment of an antiviral state also in the non-infected tissue surrounding the IFN-producing cells.

A fourth point worth discussing is the fact that the virus-induced IFN response is generated in a cascade-like manner ([Fig. 3](#fig3){ref-type="fig"}). Therefore, viral proteins blocking one component in this circuit also affect distant signaling or effector molecules, thereby amplifying their inhibitory effect. For example, JAK-STAT inhibitors not only suppress the production of antiviral proteins but also the expression of RIG-I, MDA5, IPS-1/MAVS, IRF-3 and IRF-7 which are all IFN-inducible proteins. As a consequence, production of the "second-wave" IFNs is reduced. This enhanced down-regulation of IFN responses acts against the IFN-activating effect of viral dsRNA molecules which progressively accumulate in infected cells. The end-result is a balance between virus-promoting and virus-inhibiting factors which may be optimal for each virus-host relationship.

Interestingly, some lytic viruses causing acute infections have adopted a radical strategy usually not found in non-lytic viruses that persist in the body. Poliovirus, vesicular stomatitis virus (VSV) and some bunyaviruses affect the basic cellular transcription machinery and shut-off host gene transcription ([@bib1], [@bib14], [@bib28], [@bib90], [@bib160], [@bib172], [@bib176], [@bib183]). More specifically, the non-structural protein NSs of RVFV has been demonstrated to target the p44 component of the cellular transcription factor IIH (TFIIH) which is an essential cofactor of the cellular RNA polymerase II (RNAP II) ([@bib90]). Likewise, the M protein of VSV inactivates TFIID, another RNAP II cofactor ([@bib183]). Hence, some viral proteins are suppressors of IFN gene expression through their general inhibitory effect on host gene transcription ([@bib1], [@bib14], [@bib160]). In addition, as already mentioned, the NSs of RVFV activates SOCS-1 and has a more specific but indirect effect on the JAK-STAT pathway. To be effective, NSs should be expressed at very early time points of infection. This task would seem difficult to achieve, because NSs of RVFV is transcribed in an ambisense coding strategy from the complementary anti-sense S segment which needs first to be synthesized in infected cells. However, a recent report finds that such anti-sense S segment RNAs are packaged into infectious virus particles and can be transcribed into NSs mRNA immediately after delivery to the cell cytoplasm. It is suggested that the immediate availability of NSs protein may provide a selective advantage in giving the virus a "head start" over the innate immune system ([@bib72]).

Concluding remarks and outlook
==============================

The interplay between viruses and the IFN responses of their hosts, as described here, is most likely the result of an evolutionary race between the two genetic systems. The race is ongoing, as emerging viruses compete for new hosts and attempt *trans*-species transmission causing zoonotic infections, as illustrated by recent outbreaks of SARS-coronavirus, Hendra and Nipah viruses, Ebola and Marburg viruses, or the threat of transmission of H5N1 avian influenza viruses to humans.

An emerging virus must overcome the IFN defenses of a foreign host to be successful. There is ample evidence that viral IFN antagonists exhibit a degree of species specificity and are efficient in one species but not another ([@bib16], [@bib26], [@bib116], [@bib182]). However, adaptations are likely to occur. This is best illustrated in arthropod-borne viruses. They replicate in their blood-feeding arthropod hosts and are then transmitted by bite to vertebrate hosts. To continue the transmission cycle, virus replication in the vertebrate host must proceed in the face of a vigorous IFN response. To succeed, arboviruses have evolved specific viral proteins to counteract the IFN system of the vertebrate host, as illustrated in bunyavirus infections ([@bib18], [@bib172]). As invertebrates do not have equivalent IFN genes, these viral IFN antagonists are most likely an adaptation to the mammalian host, securing virus transmission. Another interesting example is Thogoto virus (THOV), an influenza-like virus transmitted by ticks to small rodents and, occasionally, man. Its replication occurs in the cell nucleus and is sensitive to inhibition by IFN-induced mouse Mx1 and human MxA GTPases ([@bib61], [@bib84]). The Mx block inhibits a very early step in the viral multiplication cycle that affects primary transcription of the incoming genome. Since the virus cannot transcribe and replicate its genome in the presence of Mx, generation of Mx escape mutants is virtually impossible. Therefore, the prime strategy of THOV is to suppress IFN production in the vertebrate host by virtue of its ML protein and to avoid Mx expression in potential target cells, as recently demonstrated in a mouse model ([@bib76], [@bib120]).

Future applications involve the genetic manipulation of viral IFN antagonists for the development of novel candidate vaccines. Viruses with targeted deletions in genes known to code for IFN antagonists are promising candidates for live virus vaccines. They grow well in tissue culture but are highly attenuated in the host organism, due to a robust IFN and immune response. This approach has been pioneered for FLUAV ([@bib44], [@bib156]) and for bovine RSV ([@bib165]), and may likewise apply to other viruses.

Another fascinating development is the generation of viruses that may be used as oncolytic agents. Mutations in tumor cells often cripple the IFN system, favoring unhindered proliferation and protection from apoptosis ([@bib149]). As a consequence, such cells become vulnerable to virus infection. For example, PKR is switched off in tumor cells due to transformation by p21^ras^ ([@bib111]). Alternatively, defects in translational regulation render tumor cells insensitive to PKR action ([@bib9]). VSV or wild-type reoviruses are highly sensitive to inhibition by PKR ([@bib10], [@bib151]) and preferentially infect cells which have an inactivated PKR pathway ([@bib9], [@bib29]). Therefore, selectivity for tumor cells can be increased using genetically engineered viruses devoid of anti-IFN proteins. Such viruses are unable to infect IFN-competent body cells, but are still capable of efficiently replicating and destroying the IFN-deficient tumor cells. A VSV variant with mutations in the M gene inactivating its IFN-antagonistic capacity was shown to specifically lyse tumors in immunocompetent mice ([@bib150]). Similarly, an HSV-1 lacking the gene for the anti-PKR protein γ34.5 was apathogenic even when administered intracerebrally ([@bib70]), but it could destroy glioma cells ([@bib109]).

Our present knowledge of the IFN system and viral countermeasures is still limited. However, a better understanding of the intimate interplay between viruses and innate immune defenses will open new avenues for drug design, vaccine development and anti-cancer strategies.
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